DHT (Dihydrotestosterone)
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- DHT is the primary driver of androgenic alopecia — male pattern baldness — in genetically susceptible men. Hair follicles on the scalp in men with androgenetic alopecia express androgen receptors that are hypersensitive to DHT. DHT binding to these receptors shortens the anagen (growth) phase of the hair cycle, miniaturizes the follicle progressively, and eventually eliminates it. This is why finasteride and dutasteride (5α-reductase inhibitors that reduce DHT by 60–90%) are effective treatments for male pattern baldness: they address the primary biological driver. Knowing your DHT level gives quantitative context for androgenic hair loss and informs whether pharmacological management makes sense.
- DHT is the primary driver of benign prostatic hyperplasia (BPH) — the prostate enlargement that produces urinary symptoms in most men by age 60. The prostate is highly sensitive to DHT throughout a man's life; DHT drives both normal prostate development and pathological BPH. 5α-reductase inhibitors (finasteride for type 2, dutasteride for both type 1 and 2) substantially reduce DHT and reduce prostate volume by 20–30% over 2–3 years, improving urinary symptoms. DHT testing provides important baseline and monitoring context for men tracking prostate health alongside PSA.
- Topical testosterone administration raises DHT disproportionately compared to injection. When testosterone is applied to the skin (gel, cream, patch), skin-derived 5α-reductase converts a substantial portion locally to DHT, which then enters the bloodstream. Injected testosterone bypasses this skin conversion. As a result, men using topical TRT formulations commonly have DHT levels that rise to 2–3× the standard reference range even with testosterone in the normal therapeutic range. This elevated DHT produces more pronounced androgenic effects — potentially greater hair loss and prostate effects — than equivalent testosterone delivered by injection. Monitoring DHT on topical TRT is essential.
- 5α-reductase inhibitors (finasteride, dutasteride) produce significant DHT reduction that extends beyond hair and prostate effects. Finasteride reduces DHT by approximately 60–70%; dutasteride reduces it by 90–95%. The neurological effects of this DHT reduction have received increasing attention — some men experience persistent sexual and cognitive side effects after discontinuing these medications, a syndrome termed 'Post-Finasteride Syndrome.' The mechanisms are not fully characterized. This risk profile is why DHT optimization decisions should be made thoughtfully and why monitoring DHT during and after treatment is clinically useful.
- Women with androgenic symptoms (hirsutism, acne, female pattern hair loss) should also measure DHT. While DHT is primarily discussed in male contexts, women with elevated androgens — from polycystic ovary syndrome (PCOS), congenital adrenal hyperplasia, adrenal tumors, or ovarian dysfunction — often have elevated DHT that contributes to their symptom pattern. In women, DHT testing alongside total testosterone, free testosterone, DHEA-S, and 17-hydroxyprogesterone provides a complete androgen picture for investigating hyperandrogenic conditions.
The Most Potent Androgen — and Why That Matters
Testosterone is the hormone most people think of when they think of male androgens. But testosterone is not actually the most potent androgen in the body — DHT is. DHT binds the androgen receptor with 3–10 times greater affinity than testosterone, has a longer receptor dwell time, and produces a more powerful and sustained androgenic signal per molecule.
This potency difference explains why DHT — despite being present at much lower concentrations than testosterone — is responsible for the most androgenic effects that men care about in a health context: hair follicle miniaturization leading to male pattern baldness, prostate tissue growth leading to BPH, sebaceous gland stimulation contributing to acne, and, during fetal development, the formation of the external male genitalia themselves.
For men not undergoing hormonal optimization, DHT is most clinically relevant as a monitoring marker for androgenic alopecia and prostate health. For men on testosterone therapy — particularly those using topical formulations — it is a safety marker that should be tracked longitudinely.
DHT and Testosterone Therapy: The Route-Dependence Problem
One of the most practically important facts about DHT in the context of modern hormonal optimization is that DHT elevation from testosterone therapy is highly dependent on how the testosterone is administered.
Topical testosterone (gels, creams, patches applied to skin) is converted to DHT at the application site by skin 5α-reductase before entering systemic circulation. The result is a significant preferential loading of DHT into the bloodstream relative to testosterone. Clinical studies of men on testosterone gel show that DHT levels frequently rise to 2–3 times the upper limit of the reference range even when testosterone levels are within the therapeutic range. This is a well-documented and expected pharmacological effect of the topical route — not a sign of over-dosing.
Injected testosterone (testosterone cypionate, enanthate, propionate) bypasses the skin and its 5α-reductase activity. DHT conversion still occurs — primarily in the liver and other tissues — but at a much lower rate. Men on injectable testosterone typically have DHT levels within or only slightly above the standard reference range at therapeutic testosterone doses.
This route difference has meaningful clinical implications for men with androgenic alopecia or prostate concerns who are considering TRT. Switching from a topical to an injectable formulation is often the simplest way to substantially reduce DHT exposure while maintaining equivalent testosterone levels. 1
| Population | Standard Range | Notes |
|---|---|---|
| Men (baseline, no TRT) | 30–85 ng/dL | Mid-range optimal; context-dependent |
| Men (target for longevity) | 30–60 ng/dL | Lower range if hair loss or prostate concern |
| Men on injectable TRT | Typically 60–110 ng/dL | Monitor for androgenic side effects |
| Men on topical TRT | Often 100–200+ ng/dL | Route switch or 5α-RI if hair/prostate concern |
| Women (baseline) | 4–22 ng/dL | Elevated suggests hyperandrogenism (PCOS, CAH) |
| Range Type | Value (ng/dL) | Notes |
|---|---|---|
| Standard Clinical Range | Men: 30–85 ng/dL (adult) · Women: 4–22 ng/dL | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | Men (not on TRT): 30–60 ng/dL · Men on TRT: per protocol, generally targeting mid-range |
Associated with reduced all-cause mortality and extended healthspan.
Optimal DHT levels for men depend heavily on genetic susceptibility to androgenic alopecia and prostate disease. A man with no family history of hair loss and normal PSA trajectory can tolerate DHT in the upper portion of the reference range without concern. A man with significant androgenic alopecia or elevated PSA velocity may benefit from maintaining DHT in the lower portion of the range through lifestyle factors or clinical intervention. DHT should always be interpreted alongside total testosterone, free testosterone, and SHBG for complete androgen status. In men on TRT using topical formulations (gel, cream), DHT can rise substantially above the reference range — often 2–3× — because skin 5α-reductase activity is high and creates significant local DHT production.
|
Already have your results? See what your DHT (Dihydrotestosterone) and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
Does high DHT cause prostate cancer?
The relationship between DHT and prostate cancer is more nuanced than the simple narrative suggests. DHT is the primary hormonal driver of prostate tissue growth, and androgen deprivation therapy (reducing testosterone and DHT to castrate levels) is highly effective at treating advanced prostate cancer — confirming that androgen signaling is required for prostate cancer progression. However, the relationship between baseline DHT levels in healthy men and the initial development of prostate cancer is much weaker. The 'saturation hypothesis' proposed by Abraham Morgentaler suggests that androgen receptors in the prostate become saturated at relatively low androgen levels, and that additional testosterone or DHT above this saturation point has minimal additional effect on prostate tissue. Large studies of men on testosterone therapy have not shown higher rates of prostate cancer incidence compared to untreated men. The primary concern with DHT and the prostate is BPH — driving benign enlargement — rather than cancer initiation per se.
Should I take finasteride or dutasteride to lower my DHT for hair loss?
This is a clinical decision best made with a physician who can weigh your individual risk-benefit profile. The efficacy is clear: finasteride reduces DHT by ~65% and halts or reverses androgenic alopecia in 80–90% of men who take it; dutasteride is more effective at DHT reduction and has higher efficacy for hair retention. The risk profile includes sexual side effects (reduced libido, erectile dysfunction, ejaculatory changes) in approximately 5–15% of users on clinical trials, and the more recently characterized Post-Finasteride Syndrome of persistent side effects after discontinuation in a smaller subset of men. The decision depends on the extent and trajectory of hair loss, age, reproductive plans (finasteride should generally be avoided by men trying to father children), baseline DHT level, and personal risk tolerance. Monitoring DHT before, during, and after treatment provides objective data on drug effect and can inform dose adjustments.
What's the relationship between DHT and libido in men?
DHT contributes to libido through androgen receptor signaling in the brain and peripheral tissues, though testosterone (and potentially estradiol) plays the larger role in most men. The relationship is context-dependent: at baseline healthy levels, DHT supports aspects of libido and sexual function. Men with very low DHT — either from 5α-reductase inhibitors or from primary 5α-reductase deficiency — commonly report reduced libido. However, in men with already-adequate testosterone, the incremental contribution of higher DHT to libido is modest and variable. The sexual side effects of finasteride are real and documented, but their mechanism is not fully characterized — they may involve direct DHT effects on libido and sexual function, or neurosteroid effects (DHT can be converted to androsterone neurosteroids that modulate GABA-A receptors, analogous to how progesterone metabolizes to allopregnanolone).
What is a normal DHT level for men on testosterone therapy?
This varies significantly by administration route and individual 5α-reductase activity. Men on injectable testosterone (testosterone cypionate or enanthate) typically have DHT in the upper part of the normal range or mildly above it — usually 70–110 ng/dL at therapeutic testosterone levels. Men on topical testosterone (gels, creams) commonly have DHT that substantially exceeds the standard reference range — values of 120–200 ng/dL or higher are not uncommon on topical TRT. Whether this is clinically significant depends on individual susceptibility to androgenic alopecia and BPH. Men with genetic susceptibility to hair loss who are on topical TRT may want to consider switching to injectable formulations, which produce less DHT elevation, if hair loss is a priority concern. Any DHT above 150 ng/dL on TRT warrants clinical review and discussion of formulation adjustment or 5α-reductase inhibitor use if indicated.